What is AOD-9604? origin, mechanism & research.

The origin story: what AOD-9604 is

AOD-9604 is a synthetic 16-amino-acid peptide. Its sequence corresponds to the C-terminal residues 177 through 191 of human growth hormone (hGH), with an added N-terminal tyrosine intended to improve stability for laboratory and clinical handling. In other words, AOD-9604 is a small fragment cut from the tail end of the much larger 191-amino-acid growth hormone molecule, tweaked at one end so it survives long enough to be studied.

The fragment was developed by Metabolic Pharmaceuticals, an Australian biotechnology company, beginning in the late 1990s. The work built on earlier observations that the lipolytic activity of full-length hGH, which is the part of growth hormone that drives the breakdown of stored fat, did not appear to require the full 191-residue sequence. Researchers had mapped fat-mobilizing activity to the C-terminal region of the hormone. Metabolic Pharmaceuticals took that observation and asked the obvious next question: if you isolate just that fragment, do you get a clean fat-loss signal without the unwanted growth-promoting effects of the full hormone?

The naming is unusually direct for a research compound. “AOD” stands for “Anti-Obesity Drug,” and the number 9604 is an internal designator from the Metabolic Pharmaceuticals development program. The name reflects the explicit therapeutic target the molecule was designed around, which was obesity, not recovery, not anti-aging, and not the broader catalogue of off-label uses that have since accumulated in peptide therapy communities.

It is worth emphasizing one structural point that gets blurred in popular content: AOD-9604 is not human growth hormone, it is not a growth-hormone releasing hormone (GHRH) analog, and it is not a secretagogue. It does not act on the pituitary to stimulate the body’s own pulsatile GH release, which is the mechanism Sermorelin uses. It is a small peptide fragment with its own pharmacology, distinct from both recombinant hGH and the GHRH family.

Proposed mechanism of action: lipolytic without growth signaling

The central scientific premise of AOD-9604 is that the C-terminal fragment of hGH retains the hormone’s fat-mobilizing properties while losing the receptor-binding profile responsible for IGF-1 elevation, cartilage growth, and the metabolic side effects that limit recombinant hGH as a weight-loss therapy. Several biological pathways have been proposed to explain how the fragment might do this.

Direct lipolysis at the adipocyte

Preclinical work in isolated rat adipocytes and obese rodent models showed that the hGH 177-191 fragment increased the breakdown of stored triglycerides and the release of free fatty acids into circulation. This lipolytic signature is consistent with what full-length hGH does at the adipocyte. The hypothesis was that the fragment carries that activity into a smaller, more druggable molecule.

Beta-3 adrenergic axis involvement

Several preclinical studies suggested that AOD-9604’s downstream signaling overlaps with the beta-3 adrenergic receptor pathway, which is the dominant lipolytic and thermogenic pathway on white and brown adipose tissue. The fragment does not appear to be a conventional beta-3 agonist, meaning it does not bind and activate the receptor directly the way a small-molecule beta-3 drug would. The downstream signature, however, including increased cyclic AMP and hormone-sensitive lipase activity, is in the same neighborhood as beta-3 signaling. The exact upstream interaction has not been fully resolved.

Fat oxidation, not just fat release

Mobilizing fat from storage is only useful if the released fatty acids are then oxidized for energy. Otherwise they cycle back into storage or deposit ectopically in tissues such as liver and muscle. Animal studies with AOD-9604 reported increases in fat oxidation alongside lipolysis, at least in the rodent setting. Whether that pattern translates into the kind of net energy expenditure changes that produce meaningful weight loss in humans was one of the open questions the Phase 2 program was designed to answer.

The IGF-1-sparing profile

The defining pharmacological claim of AOD-9604 in published human work is the absence of meaningful change in circulating IGF-1, fasting glucose, or insulin sensitivity at the doses studied. IGF-1 is the systemic mediator for most of growth hormone’s anabolic and metabolic effects, including cartilage growth, anabolism, and insulin resistance. If a fat-loss molecule can act lipolytically without raising IGF-1, it sidesteps the side-effect profile that limits recombinant hGH for obesity. That pattern, more than the weight-loss signal itself, is what made AOD-9604 scientifically interesting.

One important caution: most of this mechanistic detail comes from the Metabolic Pharmaceuticals development program and a relatively narrow band of academic studies. The molecule has not received the volume of independent mechanistic replication that approved drugs typically generate.

The state of the evidence: animal data versus the Phase 2b human result

This is the section where the marketing version of AOD-9604 and the literature version diverge, and it is the section anyone considering the fragment should read carefully.

What the animal data showed

In rodent studies, AOD-9604 produced reproducible reductions in body fat and increases in lipolysis at biologically relevant doses, with relatively clean changes in insulin sensitivity and IGF-1. The animal data was strong enough to justify advancing the molecule into human trials, which is a substantive step. Most peptide programs do not get that far. So the preclinical signal was real, and Metabolic Pharmaceuticals had a coherent rationale for clinical development.

The Phase 2b human trial

The pivotal human study was a 24-week, multi-center, double-blind, placebo-controlled Phase 2b trial (the OPTIONS study) of oral AOD-9604 at doses of 0.25, 0.5, and 1 mg in obese adults, sponsored by Metabolic Pharmaceuticals, with weight loss at 12 weeks as the primary endpoint. The trial did not show a statistically significant difference in weight loss between AOD-9604 and placebo at the primary endpoint. That result is the load-bearing fact in the AOD-9604 evidence base, and it is the fact most heavily downplayed in pro-AOD-9604 content online.

Earlier dose-ranging Phase 2 work had shown some signal at certain doses, which is why the larger Phase 2b was undertaken. The Phase 2b did not replicate it convincingly. Following that result, Metabolic Pharmaceuticals terminated the anti-obesity development program in 2007. The molecule was not advanced to a registrational Phase 3 obesity trial, no FDA New Drug Application was filed, and no subsequent sponsor has published a successful registrational obesity program with the fragment.

What came after the obesity program ended

After the obesity program plateaued, secondary research interest shifted toward cartilage and osteoarthritis. Preclinical studies have reported chondroprotective signals in animal joint-injury models, and a smaller number of exploratory clinical investigations have looked at intra-articular administration. This second-generation research is preliminary, has not produced a registered drug, and should not be confused with established treatment for joint disease.

In a separate regulatory track, AOD-9604 received a self-affirmed Generally Recognized as Safe (GRAS) determination in the United States for limited food-ingredient and dietary-supplement contexts. GRAS is a food-ingredient safety pathway. It is not a drug approval, it is not a determination of efficacy, and it does not authorize the peptide to be marketed for the treatment of obesity or any medical condition.

The honest summary

The animal data is real and reproducible. The mechanistic premise is coherent. The pivotal Phase 2b human trial did not deliver the clean separation from placebo that would justify advancing to Phase 3, and the original developer ended the obesity program. Anyone selling AOD-9604 as a proven weight-loss therapy is overstating the human evidence base, and anyone dismissing the molecule as having no scientific premise at all is ignoring the preclinical work that justified the trial program in the first place. The reality sits in between, and it is closer to “interesting but unproven in humans” than to either pole.

FDA Category 2 and the April 15, 2026 transitional reshuffle

AOD-9604’s regulatory posture in the United States changed materially in April 2026. To understand what changed, it helps to walk through the FDA bulk-drug-substance categorization framework that governs what compounding pharmacies can and cannot prepare.

The FDA maintains category lists for substances used by 503A compounding pharmacies, which are the licensed pharmacies that prepare custom medications under a clinician’s prescription:

• Category 1 substances may be used by 503A compounding pharmacies, subject to standard rules.
• Category 2 substances are those the FDA has identified safety or quality concerns about, and which 503A pharmacies cannot compound.
• Category 3 substances remain under evaluation, with no final determination yet.

On April 15, 2026, the FDA reorganized its peptide categorization in a way that placed AOD-9604 firmly in the transitional bucket: the molecule is not on the Category 1 permitted list, and it is treated as Category 2 for the practical purposes of 503A compounding. The state-of-play following the reshuffle is that 503A pharmacies cannot compound AOD-9604 pending further review by the Pharmacy Compounding Advisory Committee (PCAC), the panel that advises FDA on these classifications.

That is the load-bearing point. PepScribe’s pharmacy standard is 503A-only by policy, which means PepScribe cannot offer AOD-9604 as a peptide-direct compounded product through any partner pharmacy in our network. Some clinics outside the 503A standard may attempt to source the peptide through other channels. PepScribe does not.

What reclassification would require

A move from transitional Category 2 status to Category 1 permitted status would require the PCAC to evaluate the substance and recommend reclassification, followed by FDA action. The substantive bar for that evaluation includes adequate human safety and efficacy data, defensible identity and characterization standards, and a clinical use case that survives review. AOD-9604’s null Phase 2b weight-loss result is the exact kind of evidence gap that makes the reclassification path unclear. Status may shift through 2026 and 2027 as the PCAC continues its peptide review work, and we will update this page as it does.

Safety considerations: what the trial program showed

Across the published Metabolic Pharmaceuticals trial program, AOD-9604 was generally well tolerated. No major safety signal emerged from the Phase 1 and Phase 2 studies, which is part of why the fragment retains research interest despite the unimpressive Phase 2b efficacy outcome.

Reported side effects

• Mild injection-site reactions with subcutaneous administration in studies where that route was used.
• Headache, generally mild and transient in the published reports.
• Occasional gastrointestinal discomfort with oral formulations.

Metabolic safety

Published human data did not show clinically meaningful changes in fasting glucose, insulin, or IGF-1 at the studied doses. That pattern is the pharmacological feature that separates AOD-9604 from recombinant hGH, and it is the most reproducible finding across the human program. From a metabolic-safety standpoint, the fragment looks distinct from the full hormone, which is the design rationale.

The unknowns

Long-term safety is not established in the way it is for FDA-approved therapeutics. The trial program had relatively small sample sizes, the follow-up windows were short, and the molecule never crossed into registrational evaluation. Drug-interaction data is sparse. Effects in pregnancy, lactation, pediatric populations, and patients with significant comorbidities are not characterized. The honest position is that short-course safety in healthy obese adults looked acceptable, and longer horizons or more complex patient profiles are not well studied.

Administration routes the research has explored

AOD-9604 was studied via two main routes in the Metabolic Pharmaceuticals program:

• Oral. The original development pathway pursued an oral formulation, partly because oral dosing is more attractive commercially for an obesity therapeutic. The pivotal 24-week Phase 2b study used oral dosing at 0.25, 0.5, and 1 mg. Oral peptide bioavailability is generally low, and that limitation is a plausible contributor to the underwhelming efficacy result, although it does not fully explain it.
• Subcutaneous. Earlier-phase human studies and animal work used subcutaneous injection. This is the route most peptide therapy communities reference today, and it bypasses the bioavailability limitations of oral administration. It is also the route most commonly seen in the gray-market injectable products that circulate online.

It is important to be precise: discussing the routes the research used is not the same as recommending administration. There is no FDA-approved product, no registered label, and no PCAC-cleared compounding protocol for AOD-9604 in the United States. Anything that names a specific dose or route outside a clinician-supervised setting under a defensible compounding framework is exceeding the evidence.

Physician-supervised peptide therapy: the broader context

AOD-9604 sits inside a wider conversation about peptide therapy that is playing out across regulatory bodies, compounding pharmacies, and clinical practice. Physician-supervised peptide therapy, when conducted through legitimate channels, has a few defining features:

• A licensed clinicianreviews the patient’s health history, current medications, lab work, and goals, and is the prescriber of record.
• Compounding through 503A pharmacies for substances that the FDA permits in 503A compounding, which AOD-9604 is not at this time.
• Ongoing monitoring through follow-up consultations and lab work as needed.
• Honest framing of evidence base, alternatives, and reasonable expectations.

Currently available alternatives for weight management

For patients who came to AOD-9604 looking for a weight-management therapy, the pragmatic answer is that the available evidence base for GLP-1 receptor agonists is dramatically deeper. Both Semaglutide and Tirzepatide have multiple large registrational Phase 3 trials, FDA-approved branded products, and clinician-prescribed compounded equivalents available through 503A pharmacies. They work through entirely different mechanisms than AOD-9604 (incretin signaling rather than direct lipolysis), and they have produced clinical weight-loss outcomes the AOD-9604 Phase 2b program did not achieve. For most weight-management goals, those are the substantive options.

How to evaluate AOD-9604 information you find online

The information environment around AOD-9604 is heavily skewed toward marketing copy from gray-market vendors and from clinics that source the peptide outside the 503A standard. Here is a no-jargon framework for reading what you find.

Red flags in pro-AOD-9604 content

• Outcome promises (“lose X pounds in Y weeks with AOD-9604”) with no reference to the Phase 2b null result.
• Claims that AOD-9604 is “FDA-approved” or “clinically proven for weight loss.” Neither is true.
• Conflation of GRAS food-ingredient status with drug approval. They are unrelated regulatory pathways.
• Sourcing from research-chemical vendors with “not for human consumption” disclaimers, repackaged as if they were pharmaceutical-grade.
• Stacking AOD-9604 with semaglutide or tirzepatide as if their evidence bases were comparable. They are not.

Red flags in anti-AOD-9604 content

• Dismissing the molecule as having no scientific basis. The mechanism is coherent and the animal data is real.
• Treating transitional Category 2 status as a permanent safety verdict rather than a regulatory framework decision pending PCAC review.
• Conflating “underwhelming efficacy in humans” with “dangerous in humans.” The trial program showed those are different findings.

What balanced evaluation looks like

• Acknowledging the legitimate scientific premise and the consistent animal pharmacology.
• Being honest that the pivotal Phase 2b human trial did not show significant weight loss versus placebo.
• Recognizing that “well tolerated short-term” is not the same as “long-term safety established.”
• Understanding that current US regulatory status precludes 503A compounding and that this is the situation, regardless of what gray-market vendors imply.
• Recognizing that for most weight-management goals, the available evidence for GLP-1 receptor agonists such as semaglutide and tirzepatide is in a different league.